enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Members of Congress who traded ENGN
No member of Congress has reported a trade in enGene Therapeutics Inc. since 2020.
Source: U.S. House Clerk and Senate Office of Public Records (eFD). Amounts are the ranges filers report.